These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14685305)

  • 1. New biophysical probes for structure-activity analyses of vacuolar-H+ -ATPase enzymes.
    Dixon N; Pali T; Ball S; Harrison MA; Marsh D; Findlay JB; Kee TP
    Org Biomol Chem; 2003 Dec; 1(24):4361-3. PubMed ID: 14685305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector.
    Páli T; Whyteside G; Dixon N; Kee TP; Ball S; Harrison MA; Findlay JB; Finbow ME; Marsh D
    Biochemistry; 2004 Sep; 43(38):12297-305. PubMed ID: 15379568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase.
    Biasotti B; Dallavalle S; Merlini L; Farina C; Gagliardi S; Parini C; Belfiore P
    Bioorg Med Chem; 2003 May; 11(10):2247-54. PubMed ID: 12713834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPR Studies of V-ATPase with Spin-Labeled Inhibitors DCC and Archazolid: Interaction Dynamics with Proton Translocating Subunit c.
    Gölz JP; Bockelmann S; Mayer K; Steinhoff HJ; Wieczorek H; Huss M; Klare JP; Menche D
    ChemMedChem; 2016 Feb; 11(4):420-8. PubMed ID: 26662886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H+-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain.
    Whyteside G; Meek PJ; Ball SK; Dixon N; Finbow ME; Kee TP; Findlay JB; Harrison MA
    Biochemistry; 2005 Nov; 44(45):15024-31. PubMed ID: 16274249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the indole class of vacuolar H(+)-ATPase inhibitors with lipid bilayers.
    Fernandes F; Loura L; Koehorst RB; Dixon N; Kee TP; Hemminga MA; Prieto M
    Biochemistry; 2006 Apr; 45(16):5271-9. PubMed ID: 16618115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
    Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity studies of the V-ATPase inhibitor saliphenylhalamide (SaliPhe) and simplified analogs.
    Garcia-Rodriguez J; Mendiratta S; White MA; Xie XS; De Brabander JK
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4393-8. PubMed ID: 26372654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of the V-ATPase inhibitors concanamycin and indole pentadiene in lipid membranes. Spin-label EPR studies.
    Páli T; Dixon N; Kee TP; Marsh D
    Biochim Biophys Acta; 2004 May; 1663(1-2):14-8. PubMed ID: 15157605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spin-labelled vacuolar-ATPase inhibitors in lipid membranes.
    Dixon N; Páli T; Kee TP; Marsh D
    Biochim Biophys Acta; 2004 Oct; 1665(1-2):177-83. PubMed ID: 15471583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new destruxin as inhibitor of vacuolar-type H+-ATPase of Saccharomyces cerevisiae.
    Vázquez MJ; Albarrán MI; Espada A; Rivera-Sagredo A; Díez E; Hueso-Rodríguez JA
    Chem Biodivers; 2005 Jan; 2(1):123-30. PubMed ID: 17191925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological effects of a new vacuolar-H,-ATPase inhibitor in colon carcinoma cell lines.
    Supino R; Scovassi AI; Croce AC; Dal Bo L; Favini E; Corbelli A; Farina C; Misiano P; Zunino F
    Ann N Y Acad Sci; 2009 Aug; 1171():606-16. PubMed ID: 19723111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperidine amides as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Flyrén K; Bergquist LO; Castro VM; Fotsch C; Johansson L; St Jean DJ; Sutin L; Williams M
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3421-5. PubMed ID: 17442567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding assays of inhibitors towards selected V-ATPase domains.
    Fernandes F; Loura LM; Fedorov A; Dixon N; Kee TP; Prieto M; Hemminga MA
    Biochim Biophys Acta; 2006 Nov; 1758(11):1777-86. PubMed ID: 16996024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The little we know on the structure and machinery of V-ATPase.
    Saroussi S; Nelson N
    J Exp Biol; 2009 Jun; 212(Pt 11):1604-10. PubMed ID: 19448070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRAK-4 inhibitors. Part 1: a series of amides.
    Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antioxidant properties of novel N-H and N-substituted propanamide derivatives.
    Olgen S; Kiliç Z; Ada AO; Coban T
    Arch Pharm (Weinheim); 2007 Mar; 340(3):140-6. PubMed ID: 17315261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney vacuolar H+ -ATPase: physiology and regulation.
    Valles P; Lapointe MS; Wysocki J; Batlle D
    Semin Nephrol; 2006 Sep; 26(5):361-74. PubMed ID: 17071330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.
    Nadler G; Morvan M; Delimoge I; Belfiore P; Zocchetti A; James I; Zembryki D; Lee-Rycakzewski E; Parini C; Consolandi E; Gagliardi S; Farina C
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3621-6. PubMed ID: 9934482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vacuolar H(+)-ATPase.
    Xiao YT; Xiang LX; Shao JZ
    Int J Biochem Cell Biol; 2008; 40(10):2002-6. PubMed ID: 17897871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.